ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Novartis to end anti-infectives R&D

by Michael McCoy
July 13, 2018 | APPEARED IN VOLUME 96, ISSUE 29

 

Novartis has decided to exit antibacterial and antiviral research. About 140 related jobs are being eliminated in Emeryville, Calif.; about 150 jobs will remain in the San Francisco Bay Area at the Novartis Institute for Tropical Diseases and at departments that support efforts focused on difficult targets. The firm says it is talking to other companies about out-licensing its antibiotic programs. They include LYS228, a compound that is being tested in clinical trials for its ability to kill Gram-negative bacteria.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment